These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1041 related items for PubMed ID: 34264341

  • 1. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS, Correa A, Contreras JP.
    Eur Heart J Cardiovasc Pharmacother; 2022 May 05; 8(3):311-321. PubMed ID: 34264341
    [Abstract] [Full Text] [Related]

  • 2. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M.
    Lancet; 2020 Sep 19; 396(10254):819-829. PubMed ID: 32877652
    [Abstract] [Full Text] [Related]

  • 3. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ, Brunton SA, Rangaswami J.
    Cardiovasc Diabetol; 2023 Nov 16; 22(1):316. PubMed ID: 37974185
    [Abstract] [Full Text] [Related]

  • 4. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S.
    Adv Ther; 2022 Feb 16; 39(2):845-861. PubMed ID: 34881413
    [Abstract] [Full Text] [Related]

  • 5. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L, Ferrari I, Cicogna F, Tota C, Calò L.
    Int J Cardiol; 2021 Oct 15; 341():56-59. PubMed ID: 34454968
    [Abstract] [Full Text] [Related]

  • 6. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
    O'Meara E, Verma S.
    Can J Cardiol; 2021 Apr 15; 37(4):669-673. PubMed ID: 33450364
    [Abstract] [Full Text] [Related]

  • 7. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
    Lioudaki E, Joslin JR, Trachanatzi E, Androulakis E.
    Rev Cardiovasc Med; 2022 Mar 03; 23(3):82. PubMed ID: 35345249
    [Abstract] [Full Text] [Related]

  • 8. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
    Starr JA, Pinner NA, Lisenby KM, Osmonson A.
    Pharmacotherapy; 2021 Jun 03; 41(6):526-536. PubMed ID: 33866578
    [Abstract] [Full Text] [Related]

  • 9. Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes.
    Vlasschaert C, Sidhu B, Silver SA.
    Curr Opin Nephrol Hypertens; 2021 May 01; 30(3):361-368. PubMed ID: 33767064
    [Abstract] [Full Text] [Related]

  • 10. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T, Ferrannini G, Mellbin L, Benson L, Cosentino F, McMurray JJV, Dahlström U, Lund LH, Savarese G.
    J Card Fail; 2022 Jul 01; 28(7):1050-1062. PubMed ID: 35550428
    [Abstract] [Full Text] [Related]

  • 11. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
    Mima A.
    Adv Ther; 2021 May 01; 38(5):2201-2212. PubMed ID: 33860925
    [Abstract] [Full Text] [Related]

  • 12. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
    Brown E, Wilding JPH, Alam U, Barber TM, Karalliedde J, Cuthbertson DJ.
    Ann Med; 2021 Dec 01; 53(1):2072-2089. PubMed ID: 33107349
    [Abstract] [Full Text] [Related]

  • 13. SGLT2 Inhibitors to Slow Chronic Kidney Disease Progression: A Review.
    Maxson R, Starr J, Sewell J, Lyas C.
    Clin Ther; 2024 Jan 01; 46(1):e23-e28. PubMed ID: 37951783
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
    Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O'Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJV.
    Circulation; 2021 Jan 26; 143(4):298-309. PubMed ID: 33040613
    [Abstract] [Full Text] [Related]

  • 15. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction.
    Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, Filippatos G, Greene SJ, McDonagh TA, Ponikowski P, Rosano G, Seferovic P, Vaduganathan M, Voors AA, Metra M.
    Eur J Heart Fail; 2022 Mar 26; 24(3):431-441. PubMed ID: 34894038
    [Abstract] [Full Text] [Related]

  • 16. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y, Kuwahara K.
    J Cardiol; 2020 Aug 26; 76(2):123-131. PubMed ID: 32340780
    [Abstract] [Full Text] [Related]

  • 17. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
    Greene SJ, Butler J, Kosiborod MN.
    Am J Med; 2024 Feb 26; 137(2S):S25-S34. PubMed ID: 38184323
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Anker SD, Zannad F, EMPEROR-Reduced Trial Committees and Investigators.
    Eur J Heart Fail; 2019 Oct 26; 21(10):1270-1278. PubMed ID: 31584231
    [Abstract] [Full Text] [Related]

  • 19. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB, McCullough PA.
    Cardiorenal Med; 2022 Oct 26; 12(3):81-93. PubMed ID: 35835083
    [Abstract] [Full Text] [Related]

  • 20. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia.
    Fernandez-Fernandez B, Sarafidis P, Kanbay M, Navarro-González JF, Soler MJ, Górriz JL, Ortiz A.
    Clin Kidney J; 2020 Oct 26; 13(5):728-733. PubMed ID: 33123352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.